|
gptkbp:instanceOf
|
gptkb:immunotherapy
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
advanced cancers
adjuvant therapy
metastatic cancers
infusion every 3 or 6 weeks
neoadjuvant therapy
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:cancer
gptkb:FDA
gptkb:head_and_neck_squamous_cell_carcinoma
gptkb:classical_Hodgkin_lymphoma
gptkb:microsatellite_instability-high_cancer
gptkb:primary_mediastinal_large_B-cell_lymphoma
gptkb:melanoma
2014
gastric cancer
|
|
gptkbp:ATCCode
|
L01XC18
|
|
gptkbp:brand
|
gptkb:Keytruda
|
|
gptkbp:CASNumber
|
1374853-91-4
|
|
gptkbp:contraindication
|
severe hypersensitivity to pembrolizumab
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
gptkb:immunotherapy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
PD-1 inhibitor
|
|
gptkbp:molecularWeight
|
146,000 g/mol
|
|
gptkbp:monitors
|
thyroid function tests
liver function tests
immune-related adverse events
pulmonary symptoms
renal function tests
|
|
gptkbp:patentExpired
|
2028 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:inflammatory_bowel_disease
nausea
diarrhea
fatigue
pruritus
hepatitis
nephritis
hypothyroidism
rash
pneumonitis
endocrinopathies
|
|
gptkbp:target
|
gptkb:programmed_cell_death_protein_1_(PD-1)
|
|
gptkbp:UNII
|
4Z3Z14G2PO
|
|
gptkbp:bfsParent
|
gptkb:L01XE23
gptkb:Keytruda
gptkb:Lenvima
gptkb:KEYNOTE-024
gptkb:Lenvatinib
gptkb:NSCLC
gptkb:Toripalimab
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pembrolizumab
|